Protagonist Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference 2025
Protagonist Therapeutics (PTGX) has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference, scheduled for January 12-16, 2025, in San Francisco. Dinesh V. Patel, Ph.D., President and CEO, will deliver a company overview presentation on Tuesday, January 14, at 8:15 AM PT.
The presentation will be available via webcast, and the company will engage in one-on-one meetings during the conference. Interested parties can arrange meetings through their J.P. Morgan representatives. A replay of the presentation will be accessible on the Company's Investor Relations Events and Presentations webpage for one year after the event.
Protagonist Therapeutics (PTGX) ha annunciato la sua partecipazione alla 43ª Conferenza Annuale J.P. Morgan Healthcare, in programma dal 12 al 16 gennaio 2025 a San Francisco. Dinesh V. Patel, Ph.D., Presidente e CEO, presenterà una panoramica dell'azienda martedì 14 gennaio, alle 8:15 AM PT.
La presentazione sarà disponibile tramite webcast e l'azienda parteciperà a incontri one-to-one durante la conferenza. Le parti interessate possono organizzare incontri tramite i loro rappresentanti J.P. Morgan. Una replica della presentazione sarà accessibile sulla pagina degli Eventi e Presentazioni delle Relazioni con gli Investitori dell'azienda per un anno dopo l'evento.
Protagonist Therapeutics (PTGX) ha anunciado su participación en la 43ª Conferencia Anual J.P. Morgan Healthcare, programada del 12 al 16 de enero de 2025 en San Francisco. Dinesh V. Patel, Ph.D., Presidente y CEO, ofrecerá una presentación sobre la empresa el martes 14 de enero a las 8:15 AM PT.
La presentación estará disponible a través de un webcast y la empresa participará en reuniones uno a uno durante la conferencia. Las partes interesadas pueden organizar reuniones a través de sus representantes de J.P. Morgan. Se podrá acceder a una repetición de la presentación en la página de Eventos y Presentaciones de Relaciones con Inversores de la empresa durante un año después del evento.
프로타고니스트 테라퓨틱스 (PTGX)는 2025년 1월 12일부터 16일까지 샌프란시스코에서 열리는 제43회 JP모건 헬스케어 컨퍼런스에 참여할 것이라고 발표했습니다. Dinesh V. Patel, Ph.D., 사장 겸 CEO는 1월 14일 화요일 오전 8시 15분 PT에 회사 개요 발표를 진행할 예정입니다.
발표는 웹캐스트를 통해 제공될 것이며, 회사는 컨퍼런스 동안 일대일 회의에도 참여합니다. 관심 있는 분들은 JP모건 담당자를 통해 회의를 조정할 수 있습니다. 발표의 재생은 행사 이후 1년 동안 회사의 투자자 관계 이벤트 및 프레젠테이션 웹페이지에서 확인할 수 있습니다.
Protagonist Therapeutics (PTGX) a annoncé sa participation à la 43e Conférence Annuelle J.P. Morgan Healthcare, qui se déroulera du 12 au 16 janvier 2025 à San Francisco. Dinesh V. Patel, Ph.D., Président et Directeur Général, présentera un aperçu de l'entreprise le mardi 14 janvier à 8h15 PT.
La présentation sera accessible par webcast et l'entreprise participera à des réunions individuelles pendant la conférence. Les parties intéressées peuvent organiser des réunions par l'intermédiaire de leurs représentants J.P. Morgan. Une rediffusion de la présentation sera disponible sur la page des Événements et Présentations des Relations Investisseurs de l'entreprise pendant un an après l'événement.
Protagonist Therapeutics (PTGX) hat seine Teilnahme an der 43. Jahreskonferenz J.P. Morgan Healthcare angekündigt, die vom 12. bis 16. Januar 2025 in San Francisco stattfinden wird. Dinesh V. Patel, Ph.D., Präsident und CEO, wird am Dienstag, den 14. Januar, um 8:15 Uhr PT eine Unternehmensübersicht präsentieren.
Die Präsentation wird über einen Webcast verfügbar sein, und das Unternehmen wird während der Konferenz individuelle Meetings durchführen. Interessierte Parteien können Meetings über ihre J.P. Morgan-Vertreter organisieren. Eine Wiederholung der Präsentation wird ein Jahr lang nach der Veranstaltung auf der Website für Investorenbeziehungen des Unternehmens in der Rubrik Veranstaltungen und Präsentationen zugänglich sein.
- None.
- None.
NEWARK, CA / ACCESSWIRE / December 19, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will provide a company overview at the 43rd Annual J.P. Morgan Healthcare Conference taking place January 12-16, 2025 in San Francisco, CA. The Company will also participate in one-on-one meetings.
43rd Annual J.P. Morgan Healthcare Conference - January 12-16, 2025
Format: Company Presentation
Day/Time: Tuesday, January 14 at 8:15AM PT
Webcast: https://jpmorgan.metameetings.net/events/healthcare25/sessions/58274-protagonist-therapeutics-inc/webcast?gpu_only=true&kiosk=true
If you are interested in meeting with the Protagonist team during the conference, please reach out to your J.P. Morgan representative.
A replay of the presentation will be available on the Company's Investor Relations Events and Presentations webpage for one year following the event.
About Protagonist
Protagonist Therapeutics is a late-stage development biopharmaceutical company. Two novel peptides derived from Protagonist's proprietary discovery platform are currently in advanced Phase 3 clinical development, with New Drug Application submissions to the FDA potentially in 2025. Icotrokinra (JNJ-2113, formerly PN-235) is the first targeted oral peptide designed to selectively block the IL-23 receptor, which underpins the inflammatory response in moderate-to-severe plaque psoriasis (PsO) and other IL-23-mediated diseases. Icotrokinra binds to the IL-23 receptor with single-digit picomolar affinity and demonstrated potent, selective inhibition of IL-23 signaling in human T cells. Icotrokinra is licensed to Johnson & Johnson and is currently in Phase 3 development for PsO and is nearing completion of Phase 2b development for ulcerative colitis. Following icotrokinra's joint discovery by Protagonist and Johnson & Johnson scientists pursuant to the companies' IL-23R collaboration, Protagonist was primarily responsible for development of icotrokinra through Phase 1, with Johnson & Johnson assuming responsibility for development in Phase 2 and beyond. Rusfertide, a mimetic of the natural hormone hepcidin, is currently in Phase 3 development for the rare blood disorder polycythemia vera. Rusfertide is being co-developed and will be co-commercialized with Takeda Pharmaceuticals pursuant to a worldwide collaboration and license agreement entered into in 2024 under which the Company remains primarily responsible for development through NDA filing. The Company also has a number of pre-clinical stage oral drug discovery programs addressing clinically and commercially validated targets, including IL-17, hepcidin mimetic, and anti-obesity programs.
More information on Protagonist, its pipeline drug candidates and clinical studies can be found on the Company's website at www.protagonist-inc.com.
Contact Information
Corey Davis Ph.D.
Investor Relations Contact - LifeSci Advisors
cdavis@lifesciadvisors.com
+1 212 915 2577
Virginia Amann
Media Relations Contact - ENTENTE Network of Companies
virginiaamann@ententeinc.com
+1 833 500 0061 ext 1
SOURCE: Protagonist Therapeutics
View the original press release on accesswire.com
FAQ
When is Protagonist Therapeutics (PTGX) presenting at the 2025 J.P. Morgan Healthcare Conference?
How can investors access the PTGX presentation at the J.P. Morgan Healthcare Conference 2025?
How long will the PTGX J.P. Morgan Healthcare Conference 2025 presentation replay be available?
How can investors arrange one-on-one meetings with PTGX at the J.P. Morgan Healthcare Conference 2025?
